Pancreatic Cancer Research

ResearcherJena University HospitalActive in the last 2 years

Utz Settmacher

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2417-7196; OpenAlex author ID A5018926438, A5041279223. Sources: OpenAlex.

Their work

Papers
9 (first author 0, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
30
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 1 paper · 2014: none · 2015: none · 2016: 2 papers · 2017: 1 paper · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: 1 paper · 2024: 1 paper

Papers 9

  1. Upregulation of the histone γ-H2AX correlates with worse patient survival and basal-like subtype in pancreatic ductal adenocarcinoma. Last author DOI 10.1007/s00432-024-05681-x↗
  2. Cytokeratin 6 identifies basal-like subtypes of pancreatic ductal adenocarcinoma with decreased survival. Last author DOI 10.1007/s00432-023-04702-5↗
  3. [Biomarkers for thromboembolic events in patients with pancreatic adenocarcinoma]. Last author DOI 10.1007/s00104-019-0905-5↗
  4. [Biomarkers for thromboembolic events in patients with pancreatic adenocarcinoma]. Last author DOI 10.1007/s00104-018-0707-1↗
  5. Elevated interferon-induced protein with tetratricopeptide repeats 3 (IFIT3) is a poor prognostic marker in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00432-017-2351-4↗
  6. Proteinase-activated receptor 2 promotes TGF-β-dependent cell motility in pancreatic cancer cells by sustaining expression of the TGF-β type I receptor ALK5. Co-author DOI 10.18632/oncotarget.9600↗
  7. Proteinase-Activated Receptor 2 Is a Novel Regulator of TGF-β Signaling in Pancreatic Cancer. Co-author DOI 10.3390/jcm5120111↗
  8. Multicenter phase II trial to investigate safety and efficacy of gemcitabine combined with cetuximab as adjuvant therapy in pancreatic cancer (ATIP). Co-author DOI 10.1093/annonc/mdt270↗
  9. Reduced expression of desmocollin 2 is an independent prognostic biomarker for shorter patients survival in pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/jclinpath-2011-200099↗

Closest collaborators

The 25 strongest of 30 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Felix Popp · 3 shared papers, 2017–2024 · strength 0.35
  2. Christiane J. Bruns · 3 shared papers, 2017–2024 · strength 0.35
  3. Yue Zhao · 3 shared papers, 2017–2024 · strength 0.35
  4. Philipp Felgendreff · 2 shared papers, 2018–2019 · strength 0.30
  5. Werner Hartwig · 2 shared papers, 2023–2024 · strength 0.29
  6. Alexander Ioannis Damanakis · 2 shared papers, 2023–2024 · strength 0.29
  7. Alexander Quaas · 2 shared papers, 2023–2024 · strength 0.29
  8. Thomas Schmidt · 2 shared papers, 2023–2024 · strength 0.29
  9. Su Ir Lyu · 2 shared papers, 2023–2024 · strength 0.29
  10. Karl Knipper · 2 shared papers, 2023–2024 · strength 0.29
  11. Bettina Rau Rau · 2 shared papers, 2023–2024 · strength 0.29
  12. Franziska Zeeh · 2 shared papers, 2016 · strength 0.11
  13. Hendrik Lehnert · 2 shared papers, 2016 · strength 0.11
  14. Hendrik Ungefroren · 2 shared papers, 2016 · strength 0.11
  15. David P. Witte · 2 shared papers, 2016 · strength 0.11
  16. Thomas Knösel · 2 shared papers, 2011–2017 · strength 0.09
  17. Peter Čamaj · 1 shared paper, 2017 · strength 0.06
  18. Hanno Nieß · 1 shared paper, 2017 · strength 0.06
  19. Ioannis Pozios · 1 shared paper, 2017 · strength 0.06
  20. Hendrik Seeliger · 1 shared paper, 2017 · strength 0.06
  21. Evelin Grage‐Griebenow · 1 shared paper, 2016 · strength 0.05
  22. Z. Hamidov · 1 shared paper, 2011 · strength 0.03
  23. Heiko Fensterer · 1 shared paper, 2013 · strength 0.03
  24. Wolfgang Ekkehard Schmidt · 1 shared paper, 2013 · strength 0.03
  25. Ralf‐Dieter Hofheinz · 1 shared paper, 2013 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.